Skip to content
HowShorted

Intellia Therapeutics, Inc. short interest in 2021

In 2021, Intellia Therapeutics, Inc.'s disclosed short interest ran from 16.37% of shares outstanding on 15 Jan 2021 to 5.74% on 31 Dec 2021, a change of -10.63 percentage points. The year's high was 16.37% on 15 Jan 2021 and its low 4.45% on 29 Oct 2021, averaging 8.64% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.35 days on 28 May 2021. Full history: Intellia Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Intellia Therapeutics, Inc. in 2021

2021 in figures

Start of year
16.37% (15 Jan 2021)
End of year
5.74% (31 Dec 2021)
Change
-10.63 pp
High
16.37% (15 Jan 2021)
Low
4.45% (29 Oct 2021)
Average
8.64%
Highest days to cover
7.35 (28 May 2021)
SEC filings marked
9

Every report in 2021

Intellia Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202116.37%5.35results (8-K)
29 Jan 202116.00%5.16
12 Feb 202114.51%6.84
26 Feb 202113.69%6.30results (8-K), 10-K filed
15 Mar 202114.79%5.39
31 Mar 202114.43%6.22
15 Apr 202112.35%6.46
30 Apr 20219.70%6.44
14 May 20219.75%5.4410-Q filed, results (8-K)
28 May 20219.60%7.35
15 Jun 20218.89%5.02
30 Jun 20216.79%1.00
15 Jul 20214.99%1.26
30 Jul 20214.95%3.36
13 Aug 20214.84%2.5310-Q filed, results (8-K)
31 Aug 20214.67%4.53
15 Sep 20214.78%4.25
30 Sep 20214.74%4.18
15 Oct 20215.02%4.01
29 Oct 20214.45%6.13
15 Nov 20214.66%5.7310-Q filed, results (8-K)
30 Nov 20215.34%5.54
15 Dec 20216.20%5.46
31 Dec 20215.74%6.27

See also: Intellia Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.